Interestingly, the hepatoprotective effects of ursodeoxycholic acid (UDCA), the keystone therapy in PBC, has been attributed in part to its inhibitory effect on mature ADAM17 formation (24). The gene discussed is ADAM17; the disease is primary biliary cholangitis.